Leaving Community
Are you sure you want to leave this community? Leaving the community will revoke any permissions you have been granted in this community.
Blog
dkNET community events and announcements in October, 2023
Dear dkNET Community,
dkNET provides updates on activities of interest to the NIDDK-supported community. You could keep up to date on these activities through our Twitter feed @dkNET_info, through our Community Calendar, or through dkNET e-mail list. If you have an event or funding opportunities you'd like to advertise, please contact us info_at_dknet.org.
dkNET News
- Upcoming webinars: The National Sleep Research Resource (NSRR) - Opportunities for Large-Scale Sleep and Circadian Data to Promote Understanding of Metabolic Diseases, presented by Dr. Susan Redline, Harvard T.H. Chan School of Public Health on Friday, October 27, 2023, from 11 am - 12 pm PT
- NIH Released a New RRID Webpage as Part of the ORIP Resources: Do you know why you need RRIDs? RRIDs are for resource identification, avoiding nickname confusion, boosting transparency & reproducibility, and exploring resource usage insights. Check it out: https://orip.nih.gov/resource-directory/research-resource-identifiers-rrids
- New Resources added to dkNET
- PKD Genome Browser (RRID:SCR_023925) is a browser that serves as a repository of variants across exomes and targeted panel sequencing of individuals with polycystic kidney disease. It is used to aggregate and harmonize exome and genome sequencing data from sequencing projects of PKD and to make summary data available to the wider scientific community.
- Acute Kidney Injury Data Portal (RRID:SCR_024407) is the UK Renal Registry collection of data from acute kidney injury patients in England.
- tfcheckpoint (RRID:SCR_023880) is the collection of transcription factors annotated according to experimental and other evidence on their function as true DbTFs. It provides a reference for both small-scale experiments and genome-scale studies. It contains a curated compendium of specific DNA-binding RNA polymerase II transcription factors.
- CarbonylDB (RRID:SCR_023924) is a curated data resource of protein carbonylation sites. It is a manually curated data resource of experimentally confirmed carbonylated proteins and sites. It provides information on other related resources such as a list of other oxidative protein modification databases, a list of protein oxidation and carbonylation prediction tools.
- CancerModels.Org (RRID:SCR_023931) is a cancer research platform that aggregates clinical, genomic, and functional data from various types of patient-derived cancer models, xenographs, organoids, and cell lines. It contains an open catalog of harmonised patient-derived cancer models. It standardises, harmonises, and integrates clinical metadata, molecular and treatment-based data from academic and commercial providers worldwide. The data is FAIR and underpins the generation and testing of new hypotheses in cancer mechanisms and personalised medicine development. PDCM Finder has expanded to organoids and cell lines and is now called CancerModels.Org. PDCM Finder was launched in April 2022 as the successor of the PDX Finder portal, which focused solely on patient-derived xenograft models.
- Health Information National Trends Survey (RRID:SCR_023943) regularly collects nationally representative data about the American public’s knowledge of, attitudes toward, and use of cancer and health-related information. HINTS data are used to monitor changes in the fields of health communication and health information technology and to create more effective health communication strategies across different populations. Weighted, nationally representative probability-based survey of civilian, non-institutionalized adults administered by the National Cancer Institute on knowledge of and attitudes toward cancer-relevant information.
- CARD (RRID:SCR_023995) is a comprehensive antibiotic resistance database. It is a bioinformatic database of resistance genes, their products, and associated phenotypes.
- GeneHancer (RRID:SCR_023953) is a database of human regulatory elements like enhancers and promoters, and their inferred target genes which are embedded in GeneCards, a human gene compendium. It contains associations between regulatory elements and target genes based on multiple sources of linking molecular data, along with distance.
- CanMETH database (RRID:SCR_023947) is a comprehensive DNA methylation database. It provides genome-wide mapping of methylation sites to target genes through integrating a large number of DNA methylation and gene expression profiles in human diseases, and to annotate methylation sites to abundant regulatory elements and TFs.
- GenomeMUSter (RRID:SCR_024214) is a web and programmatically accessible data service comprising allelic data covering strains at segregating sites. It is a mouse genetic variation service that enables multi-trait, multi-population data integration and analyses. It provides interoperation with phenotype databases, analytic tools, and other resources enabling a wealth of applications including multi-trait, multi-population meta-analysis. It is a mouse genetic resource that includes typed, sequenced, and imputed allelic states of 657 inbred mouse strains and their derivatives at 106.8M sites.
Events in October 2023
Oct. 08-11, 2023
Keystone Symposia: Circulating Metabolic Intermediates as Fuels and Signals
Metabolic diseases such as stroke, heart disease, diabetes, cancer, obesity, and NASH remain major causes of death and disability. On e reason is incomplete understanding of energy metabolism and its regulatio n. New data indicate that metabolites normally viewed as wastes or benign i ntermediates are actually important fuels and signals. For example, lactat e has emerged as an important energy substrate and succinate as a driver of muscle remodeling, reflecting the many underexplored energetic and regula tory roles of circulating metabolic intermediates. The importance of such i ntermediates, as opposed to classical “fuels” like glucose, amino acids a nd fat, opens a new perspective on how energy metabolism is controlled. Th us, this field is primed for further break-throughs – both in understandin g of new biology and in offering new targets for intervention. Scholarship application deadline: July 6, 2023. Abstract deadline: July 6, 2023.
More information: https://www.keystonesymposia.org/conferences/conference-listing/meeting?eventid=6867
Location: Snowbird Resort, Utah
Oct. 11, 2023
Diabetes Research Virtual Seminar Series: Old And New Insights Into Energy Sensing Signaling In Regulation of Muscle Glucose/Glycogen Metaboli sm: AMPK And Beyond
More information: https://diabetes-virtual-seminar.org/
Oct. 14-17, 2023
ObesityWeek
The preeminent international conference for obesity researchers and clinicians, ObesityWeek® is home to the latest developments in eviden ce-based obesity science: cutting-edge basic and clinical research, state- of-the-art obesity treatment and prevention, and the latest efforts in adv ocacy and public policy. Overcoming obesity requires multi-disciplinary app roaches. This is the conference that encompasses the full spectrum of obesi ty science: from basic science research, to translational research and cli nical application, to public policy; from diet, exercise, lifestyle, a nd psychology to medical and surgical interventions; from pediatric to ger iatric to underserved populations.
Location: Dallas, TX, USA
More information: https://obesityweek.org/
Oct. 20, 2023
Abstract Submission Deadline: Annual Cairibu Meeting: Collaborating for the Advancement of Interdisciplinary Research in Benign Urology
Location: Las Vegas, NV, USA
Oct. 20, 2023
Registration deadline: NIDDK's Data-Centric Challenge [Deadline is extended to November 3, 2023]
More information: https://dknet.org/about/dknetnews/2667
Oct. 24-25, 2023
2023 NMRI West Region Workshop
Location: Las Vegas, NV, USA
More information: https://www.niddk.nih.gov/news/me etings-workshops/2023/nmri-west-region-workshop-2023
Oct. 26-29, 2023
The second annual meeting for American Association of Extracellular Vesicles (AAEV)
The purpose of the Association is to promote the development, dissemination, integration, and utilization of knowledge in the field of EV. The Association provides a platform for researchers to learn, dissemin ate, and network with EV researchers worldwide through Annual Conferences\ , peer-reviewed journal, initiatives, and industry partnerships.
More information: https://www.aaev.org/even ts-1
Location: Boston, MA, USA
Oct. 27, 2023
dkNET Webinar: The National Sleep Research Resource (NSRR)
Join dkNET Webinar on Friday, October 27, 2023, 11 am - 1 2 pm PT
Abstract:TBA
Presenter: Susan Redline, MD , MPH, Peter C. Farrell Professor of Sleep Medicine, Professor of Epidem iology, Harvard T.H. Chan School of Public Health
Dial-in Information: https://uchealth.zoom.us/meeting/register/tZ0udOyop zIuHNKWQsmcU5aw68oSEfXdGh_u
Funding Opportunities Information and Deadlines in October 2023
Oct. 11, 2023
NIH Funding Opportunity Application Due: The Role of Sleep Deficien cy in Persons with Type 1 Diabetes: Sleep, Glycemic Control, and Cardiova scular Risk (R01 Clinical Trial Optional)
The purpose of this Notice of Funding Opportunity (NOFO) is to elucidate the contribution of sleep deficiency and circadian disruption to metabolic and cardiovascular pathobiology, disease trajectory, and treatment response in individuals living with Type 1 Diabetes (T1D). The NOFO will support clinically relevant, mechanism focused research on the interface between sleep, circadian rhythms biology, T1D and cardiovascular disease. Multi-disciplinary teams bridging sleep/circadian, diabetes, and cardiovascular research are encouraged. Proposed research should be relevant to the ultimate goal of applying sleep and circadian strategies to improve treatment and outcomes in individuals with T1D, and to mitigate related cardiovascular complications. Observational studies, epidemiology, efficacy trials and basic animal research will not be responsive to this NOFO. More information: https://dknet.org/about/dknetnews/2654Oct. 11, 2023
NIH Funding Opportunity Application Due: The Role of Sleep Deficiency in Persons with Type 1 Diabetes: Sleep, Glycemic Control, and Cardiovascular Risk (R34 Clinical Trial Optional)
This Notice of Funding Opportunity (NOFO) will support preliminary studies aimed at obtaining information necessary to guide the design of a full randomized control trial to test whether sleep and circadian targeted interventions improve the clinical course and treatment outcomes in individuals with Type 1 Diabetes (T1D). Applications should focus on pilot studies to inform practical and potentially sustainable strategies to improve processes of care and cardiometabolic health outcomes in individuals with T1D. The scope of research for this NOFO includes a range of feasibility metrics (e.g., optimizing recruitment, retention, randomization); intervention logistics (e.g., determine independent variable(s), dose-response, duration); study design/statistical considerations (e.g., determination of effect size, sample size, and statistical power; inclusion/exclusion criteria, control variables); adherence outcomes (measures of patient acceptance of, satisfaction with, and adherence to treatment); assessment of intermediate markers of the intervention (e.g. glycemic control, vascular dysfunction, inflammation, and/or neuroendocrine and metabolic function)\; and selection of primary and/or secondary outcome(s) measures. Ultimately, results from these pilot studies will be used to develop a well-powered\, evidence-based definitive clinical trial that could improve clinical care and cardiometabolic outcomes in individuals with T1D and to inform guidelines for this patient population. Transdisciplinary investigative teams including relevant expertise in sleep/circadian, T1D and cardiovascular research, as well as needed expertise in clinical trial design, biostatistics and other appropriate areas are encouraged. Studies should include active participation of children, adolescents, and/or adults with T1D. This program is not intended to develop or validate new treatments of devices for sleep and/or circadian deficiency. Animal studies will not be considered responsive to this initiative.More information: https://dknet.org/about/dknetnews/2655
Oct. 13, 2023
Funding Opportunity Application Due: Request for Proposals for the Kaiser Permanente Augmented Intelligence in Medicine and Healthcare Initiat ive (AIM-HI)
This is an announcement for a Request for Proposals for the Kaiser Permanente Augmented Intelligence in Medicine and Healthcare Initiative (AIM-HI) program, which is supported through funding from the Gordon and Betty Moore Foundation. The goal of this program is to advance research methods, identify best practices for scalability, and build capacity for effectively implementing and rigorously evaluating the use of AI/ML algorithms for diagnostic decision-making in real-world settings.The AIM-HI RFP is designed to provide 2-3 years of funding for 3 to 5 proposals of prospective studies of AI/ML effectiveness to improve diagnostic decision-making in US health systems with a total budget of up to $750,000 for each project. The Kaiser Permanente Division of Research will serve as the Coordinating Center for this portfolio working under the guidance of a National Advisory Committee to select funded proposals, assess study progress, lead domain working groups and disseminate best practices to build the capacity for effective AI/ML implementation in healthcare. Letter of Intent Due: June 30, 2023. Application Due: October 13, 2023.More information: https://dknet.org/about/dknetnews/2643
Oct. 16, 2023
NIDDK Funding Opportunity Letter of Intent Due: A Consortium for Gut-Brain Communication in Parkinson’s Disease (U24 Clinical Trial not allowed)
The purpose of this Notice of Funding Opportunity (NOFO) is to establish a Coordinating and Data Management Center (CDMC) that will coordinate and manage the activities of the Gastroenterology Neurology Research Centers (GNRCs), as described in the companion NOFO, RFA-DK-22-036, as part of the Gut Brain Parkinson's Disease Consortium (GBPDC). The responsibilities of the CDMC include, but are not limited to: (1) development of study protocols and coordination of enrollment of subjects into the study; (2) management of consortium-wide meetings and conferences, and cross-consortium collaborative activities; (3) provision of statistical and computational analysis support; and (4) establishing a central data hub for data capture, curation and management, and protocol development and registration. The CDMC will manage GBPDC-wide reporting and data and specimen sharing requirements, to include coordination of distribution of blood, biopsies, and other biological samples to the GNRCs. The CDMC will also manage the operations of the GBPDC Steering Committee and other operational committees and provide the infrastructure for the efficient design and conduct of multicenter studies and establish a repository of participant samples that may be used for ancillary studies of etiology and pathogenesis. NIDDK encourages applications from institutions that foster a diverse research environment, (for more information, see, e.g., NOT-OD-20-031), and encourages Research on Sex/Gender Differences, Sexual and Gender Minority-Related Research and Race/Ethnic Diversity (see NOT-DK-22-003). Application Due Date: November 15, 2023.More information: https://grants.nih.gov/grants/guide/r fa-files/rfa-dk-23-001.html
Oct. 16, 2023
NIDDK Funding Opportunity Letter of Intent Due: A Consortium for Gut-Brain Communication in Parkinson’s Disease (U01 Clinical Trial Not Allowed)
This Notice of Funding Opportunity (NOFO) invites new applications to participate in the Gut-Brain Communication in Parkinson’s Disease (PD) Consortium (GBPDC). The GBPDC will consist of up to six Gastroenterology Neurology Research Centers (GNRC) and one Coordinating and Data Management Center (CDMC). The CDMC is fully described in the companion NOFO, RFA-DK-23-001. The GNRC will serve as sites for enrollment of PD patients with and without GI symptoms as well as those with identifiable risk factors for PD, and healthy age-matched controls. Biological samples obtained from these participants will be used for laboratory-based studies. The overall objectives of this consortium are 1) to accelerate research on the role of gastrointestinal (GI) symptoms and changes in gut-brain communication in the initiation and pathogenesis of Parkinson’s disease; and 2) to facilitate development and validation of innovative early-phase gut-brain based diagnostic tools and biomarkers for PD. The activities of the GBPDC will include, but are not limited to,:1) harmonize participant recruitment and use of standardized protocols to collect data and biospecimens relevant to both neurology and gastroenterology research; 2) share data, biosamples, models, reagents, resources, and methods among projects in the GBPDC; and 3) make these publicly available through the CDMC. NIDDK encourages applications from institutions that foster a diverse research environment, (f or more information, see, e.g., NOT-OD-20-031) , and encourage Research on Sex/Gender Differences, Sexual and Gender Minority-Related Research and Race/Ethnic Diversity (see NOT-DK-22-003). Application Due Date: November 15, 2023.More information: https://grants.nih.gov/grants/guide/rfa-files/rfa-dk-22-036.html
Oct. 19, 2023
NIH Funding Opportunity Application Due: Identification and Characterization of Bioactive Microbial Metabolites for Advancing Research on Microbe-Diet-Host Interactions (R01 Clinical Trial Not Allowed)
The purpose of the Funding Opportunity Announcement is to invite applications to identify and characterize microbial metabolites that will establish causal associations between microbial metabolism and host health and disease. Data acquired through this initiative will be used to create a knowledgebase of microbial metabolites and associated functions that will be provided to the research community. Development of the database and knowledge portal for these awards will be supported under a separate initiative: RFA-DK-21-014, Identification and Characterization of Bioactive Microbial Metabolites for Advancing Research on Microbe-Diet-Host Interactions Knowledgebase Management Center (Clinical Trial Not Allowed).Letter of Intent Deadline: September 20, 2021; May 20, 2022; September 20, 2022; May 19, 2023 and September 19, 2023
Application Deadline: October 20, 2021; June 22, 2022; October 20, 2022; June 22, 2023; October 19, 2023
More Information: https://grants.nih.gov/grants/guide/pa-files/par-21-253.html
Oct. 25, 2023
NIDDK Funding Opportunity Application Due: Postbaccalaureate Research Education Program in Diabetes, Endocrinology and Metabolic Diseases (R25 – Independent Clinical Trial not Allowed)
This Funding Opportunity Announcement (FOA) provides support to eligible, domestic institutions to develop and implement Postbaccalaureate Research Education Programs in Diabetes, Endocrinology and Metabolic Diseases (DDEMD). These post-baccalaureate research programs will incorporate extensive research experiences and well-designed courses for skills development to prepare recent college graduates from diverse backgrounds to transition into and complete rigorous, research-focused biomedical doctoral degree programs (e.g., Ph.D. or M.D./Ph.D.). The long-term goal of post-baccalaureate participants admitted to the program should be pursuing a career focused on DDEMD-related research. Eligible applicants for the R25 must be research-intensive doctoral degree-granting institutions with a research base in DDEMD science of at least $3 million in direct costs of peer-reviewed research projects, and research opportunities for students admitted to the program must be in DDEMD science. Application Due Date: October 25, 2023.More information: https://grants.nih.gov/grants/guide/rfa-files/rfa-dk-22-0 37.html
Oct. 26, 2023
NIDDK Funding Opportunity Application Due: Collaborative Research Using Biosamples from Type 1 Diabetes Clinical Studies (R01 - Clinical Trial Not Allowed)
This Funding Opportunity Announcement (FOA) invites applications for studies of type 1 diabetes etiology and pathogenesis using data and samples from clinical trials and studies. This opportunity is intended to fund investigative teams collaborating to answer important questions about disease mechanisms leading to improved prevention of type 1 diabetes.Letter of Intent Deadline: January 28, 2022 ; September 26, 2023Application Deadline: February 28, 2023 ; October 26, 2023
More Information: https://grants.nih.gov/grants/guide/rfa-files/rfa-dk-22-021.html
Oct. 26, 2023
NIDDK Funding Opportunity Application Due: Clinical, Behavioral, and Physiological Studies of Open- and Closed-loop Platforms: Toward Personalized, Fully Automated, Accessible Systems (R01 Clinical Trial Required)
The purpose of this funding opportunity announcement (FOA) is to promote clinical research using current and emerging technologies to address barriers that limit progress toward physiological pancreatic hormone replacement open- and closed-loop systems. It will support research to: 1) test and improve the safety, reliability, and clinical efficacy of these technologies; 2) address behavioral/psychosocial factors that play a role in the usability and acceptance of these systems and validation of measures that may be used as outcomes for the demonstration of efficacy and benefit; 3) test these technologies in subpopulations of patients not usually included in clinical trials who may benefit the most from their use; 4) test these technologies in individuals who are underserved or in low income and/or racial and ethnic minority groups, and better understand disparities in the use and adoption of these systems; and 5) use the technologies as tools to advance understanding of glucose regulation and its pathophysiology in patients with type 1 diabetes (T1D) including counter-regulation and impaired awareness of hypoglycemia. Research goals include improved metabolic control with decreased glycemic excursions, prevention of acute and chronic complications, and improved quality of life in patients with diabetes and their caregivers. Only human studies will be considered responsive to this FOA, applications involving animal or in vitro studies are not responsive to this FOA.Letter of Intent Deadline(s): January 28, 2023; September 26, 2023
Application Deadline(s): February 28, 2023; October 26, 2023
More Information: https://grants.nih.gov/grants/guide/rfa-files/rfa-dk-22-020.html
Oct. 26, 2023
NIDDK Funding Opportunity Application Due: Evaluating Neurocognitive Complications of Pediatric Type 1 Diabetes (T1D) and Potential Risk and Protective Factors – Clinical Centers (U01 Clinical Trial Not Allowed)
The purpose of this Notice of Funding Opportunity (NOFO) is to establish a clinical consortium to better understand the neurocognitive impact of new onset type 1 diabetes (T1D) in pre-pubertal children. Clinical Centers (CCs) will establish a diverse cohort of pre-pubertal children newly diagnosed with T1D and will evaluate disease-related perturbations in neurocognitive function, as well as identify potential clinical, developmental, and/or environmental factors associated with neurocognitive function in T1D. A separate NOFO (RFA-DK-23-009) will establish a Biostatistics Research Center (BRC) to oversee the development and coordination of a core protocol to be adopted by each CC awarded under the current NOFO (RFA-DK-23-010).
The PD(s)/PI(s) of the BRC and the PD(s)/PI(s) from each of the CCs selected via RFA-DK-23-010 will form a cooperative research consortium in conjunction with NIDDK to design and implement a uniform protocol across approximately 10 CCs and the BRC. Findings from this observational study are expected to advance our understanding of the impact of T1D on the developing brain and identify risk and protective factors associated with neurocognitive functioning to ultimately inform on effective strategies to decrease adverse neurodevelopmental outcomes and long-term neurocognitive sequelae of T1D. Letter of Intent Due Date: September 26, 2023. Application Due Date: October 26, 2023.
More information: https://grants.nih.gov/grants/guide/rfa-files/rfa-dk-23-010.html
Oct. 26, 2023
NIDDK Funding Opportunity Application Due: Evaluating Neurocognitive Complications of Pediatric Type 1 Diabetes (T1D) and Potential Risk and Protective Factors – Biostatistics Research Center (U01 Clinical Trial Not Allowed)
This Notice of Funding Opportunity (NOFO) invites applications for a Biostatistics Research Center (BRC) to participate in a clinical consortium to better understand the neurocognitive impact of new onset type 1 diabetes (T1D) in pre-pubertal children. A separate RFA (RFA-DK-23-010) invites Clinical Centers (CCs) to establish a diverse cohort of pre-pubertal children newly diagnosed with T1D and will longitudinally evaluate disease-related perturbations in neurocognitive function, as well as identify potential clinical, developmental, and/or environmental factors associated with neurocognitive function in T1D.
The PD(s)/PI(s) of the BRC and the PDs/PIs from each of the CCs selected via RFA-DK-23-010 will form a cooperative research consortium in conjunction with NIDDK to design and implement a uniform protocol across approximately 10 CCs and the BRC. Findings from this observational study are expected to advance our understanding of the impact of T1D on the developing brain and identify risk and protective factors associated with neurocognitive functioning to ultimately inform on effective strategies to decrease adverse neurodevelopmental outcomes and long-term neurocognitive sequelae of T1D. Letter of Intent Due Date: September 26, 2023. Application Due Date: October 26, 2023.
More information: https://grants.nih.gov/grants/guide/rfa-files/rfa-dk-23-009.html
Oct. 26, 2023
NIDDK Funding Opportunity Application Due: Integration of Novel Measures for Improved Classification of Type 2 Diabetes – Biostatistics Research Center (U01 Clinical Trial Not Allowed)
This NOFO invites applications for a Biostatistics Research Center to participate in a consortium aimed at improving understanding of heterogeneity of type 2 diabetes (T2D). A separate NOFO (RFA-DK-23-019) will bring together investigative teams for integration of multiple data types, including markers of organ or tissue function, into analysis approaches for stratifying individuals T2D and developing more precise definitions of disease. The ultimate goal of this effort will be to 1) develop a broadly applicable framework for identifying subtypes of T2D; and 2) increase understanding of the physiologic drivers of T2D subtypes to guide development of more effective precision interventions. Letter of Intent Due Date: September 26, 2023. Application Due Date: October 26, 2023.More information: https://grants.nih.gov/grants/guide/rfa-files/rfa-dk-23-020.html
Oct. 26, 2023
NIDDK Funding Opportunity Application Due: Integration of Novel Measures for Improved Classification of Type 2 Diabetes (U01, Clinical Trials Not Allowed)
The purpose of this NOFO is to create a consortium to bring together investigative teams for integration of multiple data types, including markers of organ or tissue function, into analysis approaches for stratifying individuals with type 2 diabetes (T2D) and developing more precise definitions of disease. The ultimate goal of this effort will be to 1) develop a broadly applicable framework for identifying subtypes of T2D; and 2) increase understanding of the physiologic drivers of T2D subtypes to guide development of more effective precision interventions. Letter of Intent Due Date: September 26, 2023. Application Due Date: October 26, 2023.More information: https://grants.nih.gov/grants/guide/rfa-files/rfa-dk-23-019.html
Search
Recent dkNET Blog
dkNET Blog Tags
About
The NIDDK Information Network (dkNET) serves the needs of basic and clinical investigators by providing seamless access to large pools of data and research resources relevant to the mission of The National Institute of Diabetes Digestive and Kidney Diseases (NIDDK). dkNET is hosted at University of California San Diego, and is supported by NIH NIDDK grant 2U24DK097771-09.
Contact Us
Email: info_at_ dknet.org
